R(-)-2-Dimethylaminobutanol-(1) | 30608-60-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: R(-)-2-Dimethylaminobutanol-(1)
• 英文别名: (R)-2-dimethylamino-butan-1-ol；(R)-2-dimethylaminobutanol；(2R)-2-(dimethylamino)butan-1-ol
• CAS: 30608-60-7
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: LUWCDIUTGJVEQX-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  R(-)-2-Dimethylaminobutanol-(1) 在 1,4-二氧六环 、 Trioxane 、 sodium 作用下， 生成 ((R)-1-butoxymethyl-propyl)-dimethyl-amine
  参考文献：
  名称：

  Some Strongly Basic Derivatives of (+)- and (-)-1-Hydroxy-2-aminobutane¹

  摘要：

  DOI：

  10.1021/ja01646a033
• 作为产物：
  描述：

  聚合甲醛 、 2-氨基丁醇 在 甲酸 作用下， 以 水 为溶剂， 生成 R(-)-2-Dimethylaminobutanol-(1)
  参考文献：
  名称：

  Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators

  摘要：

  本发明涉及取代杂环芳基哌啶衍生物作为黑色素皮质素-4受体调节剂，特别是作为黑色素皮质素-4受体拮抗剂。这些拮抗剂可用于治疗由癌症、慢性肾病（CKD）或慢性心力衰竭（CHF）引起的消瘦症、肌肉消耗、由化疗或放疗引起的厌食症、神经性厌食症、肌萎缩侧索硬化症（ALS）、疼痛、神经性疼痛、焦虑和抑郁症、恶心和呕吐等疾病和疾病的治疗。

  公开号：

  EP2210885A1

文献信息

• Synergistin derivatives and pharmaceutical compositions which contain
  申请人：Rhone-Poulenc Sante

  公开号：US04798827A1

  公开（公告）日：1989-01-17

  The invention provides new synergistin derivatives of formula ##STR1## in which Y is hydrogen or dimethylamino and R is a 3- or 4-quinuclidinyl radical, the isomers thereof and their mixtures, and their salts, also the preparation thereof. These compounds may be made by reaction of the corresponding 5-methylene compounds with the appropriate mercaptoquinuclidine. The products of formula (I), optionally combined with pristinamycin II.sub.A or a derivative of pristinamycin II.sub.B of the formula ##STR2## are useful as antimicrobials.

  本发明提供了通式##STR1##所示的新协同霉素衍生物，其中Y为氢或二甲氨基，R为3-或4-喹核碱基，及其异构体和它们的混合物，以及它们的盐，还包括它们的制备方法。这些化合物可通过相应的5-亚甲基化合物与适当的巯基喹核碱反应制得。通式(I)的产品，可选择性地与普拉霉素II.sub.A或其衍生物普拉霉素II.sub.B的通式##STR2##结合，作为抗微生物剂使用。
• Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2210885A1

  公开（公告）日：2010-07-28

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression, nausea and emesis.

  本发明涉及取代杂环芳基哌啶衍生物作为黑色素皮质素-4受体调节剂，特别是作为黑色素皮质素-4受体拮抗剂。这些拮抗剂可用于治疗由癌症、慢性肾病（CKD）或慢性心力衰竭（CHF）引起的消瘦症、肌肉消耗、由化疗或放疗引起的厌食症、神经性厌食症、肌萎缩侧索硬化症（ALS）、疼痛、神经性疼痛、焦虑和抑郁症、恶心和呕吐等疾病和疾病的治疗。
• Pristinamycin II.sub.B derivatives and compositions containing them
  申请人：Rhone-Poulenc Sante

  公开号：US04668669A1

  公开（公告）日：1987-05-26

  Pristinamycin II.sub.B derivatives of formula: ##STR1## in which R denotes a nitrogen-containing 4 to 7-membered heterocyclic ring optionally substituted by alkyl; or alkyl (2 to 4 C) substituted by 1 or 2 phenyl, cycloalkylamino or N-alkyl-N-cycloalkylamino (3 to 6 ring atoms), alkylamino, dialkylamino or dialkylcarbamoyloxy radicals (the dialkylamino moieties of these 2 latter radicals being capable of forming a 4 to 7-membered cyclic ring optionally substituted by alkyl) or substituted by 1 or 2 nitrogen-containing 4 to 7 membered heterocyclic rings, optionally substituted by alkyl, at least one of the above substituents being a nitrogen-containing substituent capable of forming salts and n is 1 or 2, all the alkyls being linear or branched and containing (unless stated otherwise) 1 to 10 carbon atoms, their isomers, their salts and their preparation. These compounds, optionally in combination with known synergistins or synergistins of formula: ##STR2## are useful as antimicrobial agents.

  Pristinamycin II.sub.B的衍生物的化学式如下：##STR1##其中R代表一个含氮的4至7元杂环，该环可以选择性地被烷基取代；或者是烷基（2至4个碳原子）被1或2个苯基、环烷基氨基或N-烷基-N-环烷基氨基（3至6个环原子）、烷基氨基、二烷基氨基或二烷基氨基羰氧基取代（后两者的二烷基氨基团可以形成一个4至7元杂环，可以选择性地被烷基取代），或者是被1或2个含氮的4至7元杂环取代，这些环可以选择性地被烷基取代，上述取代基中至少有一个是能形成盐的含氮取代基，n为1或2，所有烷基都是直链或支链烷基，含有1至10个碳原子，它们的异构体、盐和制备方法。这些化合物与已知的协同素或化学式为：##STR2##的协同素结合使用作为抗微生物剂。
• Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
  申请人：Henneböhle Marco

  公开号：US20100249093A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代杂环基哌啶衍生物作为黑色素-4受体调节剂。根据化合物的结构和立体化学，本发明的化合物可以是人类黑色素-4受体（MC-4R）的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病，而拮抗剂可用于治疗癌症消耗症、肌肉萎缩、厌食症、肌萎缩侧索硬化症（ALS）、焦虑和抑郁症等疾病和疾病。通常，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物治疗。
• SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2176250A1

  公开（公告）日：2010-04-21